Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial
Mendeley Supplemental Figures for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial. J Am Acad Dermatol. 2022.
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Dataset |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!